Literature DB >> 6812115

Reinforcing properties of clonidine in rhesus monkeys.

W L Woolverton, W D Wessinger, R L Balster.   

Abstract

Intravenous clonidine self-administration was studied in rhesus monkeys under conditions of limited and unlimited access. Limited access consisted of daily 2-h experimental sessions with drug available on a fixed ratio 10 schedule. For unlimited access, drug was available 23 h/day with each response resulting in an injection. In all animals under both conditions, responding was maintained at levels that were above those maintained by saline injections at doses between 0.3 and 10 microgram/kg/inj, and the number of injections taken per session depended upon the dose. Under conditions of limited access, peak self-administration rates varied between animals but averaged approximately 30 inj/session. Total session intake was occasionally in excess of 1.0 mg/kg. Under conditions of unlimited access animals frequently self-administered more than 300 inj/day and intakes averaging 3.6 mg/kg/day occurred at the highest dose tested (10 microgram/kg/inj). When saline was substituted for clonidine after periods of clonidine access that ranged from 10-40 days, withdrawal signs included facial flushing, refusal of preferred food, restlessness, salivation, and emesis. These signs could be reversed with IV clonidine but could not be reliably precipitated with IV naloxone.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6812115     DOI: 10.1007/bf00436094

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  27 in total

1.  Self-administration of psychomotor stimulant drugs: the effects of unlimited access.

Authors:  C E Johanson; R L Balster; K Bonese
Journal:  Pharmacol Biochem Behav       Date:  1976-01       Impact factor: 3.533

2.  Psychomotor stimulant self administration as a function of dosage per injection in the rhesus monkey.

Authors:  M C Wilson; M Hitomi; C R Schuster
Journal:  Psychopharmacologia       Date:  1971

3.  Characterization of the clonidine withdrawal syndrome in the normotensive rat.

Authors:  P DiStefano; G Fox; E M Johnson
Journal:  J Pharmacol Exp Ther       Date:  1980-08       Impact factor: 4.030

4.  The effects of treatment and of withdrawal of treatment with guanfacine and clonidine on blood pressure and heart rate in normotensive and renal hypertensive rats.

Authors:  R Salzmann
Journal:  J Pharm Pharmacol       Date:  1979-04       Impact factor: 3.765

5.  Withdrawal syndrome upon cessation of chronic clonidine treatment in rats.

Authors:  R K Dix; E M Johnson
Journal:  Eur J Pharmacol       Date:  1977-07-15       Impact factor: 4.432

6.  Abrupt discontinuation of clonidine therapy.

Authors:  C V Ram; K Engelman
Journal:  JAMA       Date:  1979-11-09       Impact factor: 56.272

7.  Clonidine withdrawal. Mechanism and frequency of rebound hypertension.

Authors:  G G Geyskes; P Boer; E J Dorhout Mees
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

8.  The physiological disposition of 2(2,6-dichloroanilino)-2-imidazoline (St-155).

Authors:  A K Cho; S H Curry
Journal:  Biochem Pharmacol       Date:  1969-02       Impact factor: 5.858

9.  Opiate withdrawal using clonidine. A safe, effective, and rapid nonopiate treatment.

Authors:  M S Gold; A C Pottash; D R Sweeney; H D Kleber
Journal:  JAMA       Date:  1980-01-25       Impact factor: 56.272

10.  Tolerance and dependence after chronic administration of clonidine to the rat.

Authors:  D R Meyer; R El-Azhary; D W Bierer; S K Hanson; M S Robbins; S B Sparber
Journal:  Pharmacol Biochem Behav       Date:  1977-09       Impact factor: 3.533

View more
  10 in total

1.  Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access.

Authors:  Sunmee Wee; Chitra D Mandyam; Dusan M Lekic; George F Koob
Journal:  Eur Neuropsychopharmacol       Date:  2007-10-24       Impact factor: 4.600

Review 2.  Intracranial self-stimulation to evaluate abuse potential of drugs.

Authors:  S Stevens Negus; Laurence L Miller
Journal:  Pharmacol Rev       Date:  2014-07       Impact factor: 25.468

Review 3.  Pharmacokinetic changes in the elderly. Do they contribute to drug abuse and dependence?

Authors:  V Ozdemir; J Fourie; U Busto; C A Naranjo
Journal:  Clin Pharmacokinet       Date:  1996-11       Impact factor: 6.447

4.  Catecholamine metabolism during clonidine withdrawal.

Authors:  P R Martin; M H Ebert; E K Gordon; H Weingartner; I J Kopin
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

5.  Clonidine produces a conditioned place preference in rats.

Authors:  K E Asin; D Wirtshafter
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 6.  Adrenaline rush: the role of adrenergic receptors in stimulant-induced behaviors.

Authors:  Karl T Schmidt; David Weinshenker
Journal:  Mol Pharmacol       Date:  2014-02-05       Impact factor: 4.436

7.  Differential mechanisms in the acquisition and expression of heroin-induced place preference.

Authors:  T H Hand; L Stinus; M Le Moal
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

8.  Role of L-type calcium channels on yohimbine-precipitated clonidine withdrawal in vivo and in vitro.

Authors:  M Barrios; I Robles; J M Baeyens
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-12       Impact factor: 3.000

Review 9.  Elevated Norepinephrine may be a Unifying Etiological Factor in the Abuse of a Broad Range of Substances: Alcohol, Nicotine, Marijuana, Heroin, Cocaine, and Caffeine.

Authors:  Paul J Fitzgerald
Journal:  Subst Abuse       Date:  2013-10-13

Review 10.  The Involvement of Norepinephrine in Behaviors Related to Psychostimulant Addiction.

Authors:  Magdalena Zaniewska; Małgorzata Filip; Edmund Przegalinski
Journal:  Curr Neuropharmacol       Date:  2015       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.